Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares. [6][7][8] It is a human monoclonal antibody targeted at interleukin-1 beta.

ILARIS ® (canakinumab) is an interleukin-1β blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including:

2023年8月16日 · What is canakinumab? Canakinumab is a monoclonal antibody that blocks certain proteins in the body that can affect inflammation and other immune responses. Canakinumab is used to treat certain types of periodic fever syndromes, sometimes called auto-inflammatory syndromes.

2017年9月21日 · We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a...

2025年2月1日 · Canakinumab injection is used to treat cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). CAPS is a rare, inherited disease of the immune system.

Canakinumab is an interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).

ILARIS is indicated for the treatment of Tumor Necrosis Factor (TNF) receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients. ILARIS is indicated for the treatment of...

Ilaris® is a brand of canakinumab that treats arthritis. This condition causes pain and inflammation in your joints. Ilaris also treats rare periodic fever syndromes that cause fever episodes that don’t have an infectious cause. A healthcare provider will give you this injection.

Canakinumab (ACZ885, Ilaris) is a human anti-IL-1β monoclonal antibody developed by Novartis. its mode of action is based on the neutralization of 1β signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin.

IIlaris (canakinumab) treats certain types of periodic fever syndromes, Still’s Disease, and gout flares. Ilaris is an interleukin-1 beta (IL-1β) blockers.